A new tool to help predict survival for grade 2 and 3 meningioma
Original title: Development and internal validation of a survival prediction model for grade II/III intracranial meningioma using NCDB data.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
Built from past patient records, but not yet tested on new patients.
The short version
Researchers built an online tool that may help doctors talk with patients about survival in higher-grade meningioma.
What was studied. Researchers looked back at records from a large US cancer database. They studied 1728 adults with grade 2 or grade 3 meningioma, a brain tumor, found between 2004 and 2023.
What they found. Of the 1728 patients, 1484 had grade 2 tumors and 244 had grade 3 tumors. The team built a tool that predicts survival at 1, 3, and 5 years after diagnosis. When they checked the tool with the same data, it did a good job. They also made a free online calculator for doctors to use.
What this means, and what it doesn't
What it could mean: Someday this tool may help your doctor give you a clearer, more personal picture of what to expect. It may also help guide talks about treatment choices.
What it doesn't mean: This is not a new treatment, and it is not a cure. The tool was only checked with the same records used to build it. It still needs to be tested on other groups of patients. A prediction is a best guess based on past patients. It cannot tell exactly what will happen to you.
Source: PubMed, September 11, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.